期刊文献+

荧光原位杂交技术检测少枝胶质瘤1p染色体的杂合性缺失 被引量:1

Detection of loss of heterozygosity on chromosome 1p in oligodendrogliomas by fluorescence in situ hybridization
原文传递
导出
摘要 目的观察少枝胶质瘤中1p染色体的杂和性缺失。方法使用荧光原位杂交技术对16例少枝胶质瘤标本及5例正常对照脑组织行1p染色体检测。结果在16例少枝胶质瘤中有10例有1p染色体的杂合性缺失,占62.5%,其中6例Ⅱ级肿瘤中有5例缺失,10例Ⅲ级肿瘤中有5例缺失。结论1p染色体杂合性缺失是少枝胶质瘤的重要分子生物学特征,通过荧光原位杂交技术,可对这两类少枝胶质瘤有效地加以区分,并用于进一步的临床诊断和治疗。 Objective To explore the incidence of loss of heterozygosity (LOH) on chromosome 1 p in Chinese oligodendrogliomas. Methods Sixteen specimens of oligodendrogliomas and 5 specimens of normal control cerebral tissues (gained from the decompression operation of brain trauma) were examined by fluorescence in situ hybridization (FISH). Results Of the 16 cases of oligodendrogliomas, 10 cases (62.5%) had LOH on chromosome lp;Of the 6 cases of Ⅱ grade oligodendrogliomas,5 cases had LOH on chromosome 1p;Of the 10 cases of Ⅲ grade oligodendrogliomas,5 cases had LOH on chromosome lp. Conclusion LOH on chromosome 1 p is a most important molecular biological character of oligodendrogliomas, and oligodendrogliomas can be distinguished by FISH method effectively.
出处 《中华实验外科杂志》 CAS CSCD 北大核心 2009年第9期1111-1113,共3页 Chinese Journal of Experimental Surgery
关键词 少枝胶质瘤 染色体 杂合性缺失 荧光原伉杂交 Oligodendroglioma Chromosome Loss of heterozygosity Fluorescence in situ hybridzation
  • 相关文献

参考文献16

  • 1Kleihues P, Cavenee WK. Pathology and genetics of tumors of the nervous system. World Health Organization Classification of Tumors. Lyon : 1ARC Press ,2000:72-77.
  • 2Reifenberger G, Louis D. Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology. J Neuropathol Exp Neurol,2003, 62 : 111-126.
  • 3Engelhard HH, Stelea A, Cochran EJ, et al. Oligodendroglioma: pathology and molecular biology. Surg Neurol,2002 ,58 : 111-117.
  • 4Engelhard HH, Stelea A, Mundt A. Oligodendroglioma and anaplastic oligodendroglioma: clinical features, treatment, and prognosis. Surg Neurol,2003 ,60 :443-456.
  • 5Tanaka Y,Yokoo H,Komori T,et al. A distinct pattern of Olig2-posirive celluar distribution in papillary glioneuronal tumors:a manifestation of the oligodendroglial phenotype. Acta Neuropathol,2005,110 : 39-47.
  • 6Kros JM, Gorlia T, Kouwenhoven MC, et al. Panel review of anaplastic oligodendroglioma from European organization for research and treatment of cancer trial 26951 : assessment of consensus in diagnosis, in- fluence of 1p/19q loss, and correlations with outcome. J Neuropathol Exp Neurol,2007,66:545-551.
  • 7Burger PC, Rawlings CE, Cox EB, et al. Clinicopathologic correlations in the oligodendroglima. Cancer, 1987,59:1345-1352.
  • 8Hamlat A, Saikali S, Chaperon J, et al. Proposal of a scoring scale as a survival predictor in intracranial oligodendrogliomas. J Neurooncol, 2006,79 : 159-168.
  • 9Ozyigit G, Onal C, Gurkaynak M,et al. Postoperative radiotherapy and chemotherapy in the management of oligodendroglioma:singlie institutional review of 88 patients. J Neurooncol,2005,75:189-193.
  • 10Ueki K, Nishikawa R, Nakazato Y, et al. Correlation of histology and molecular genetic analysis of 1 p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors. Clin Cancer Res,2002,8 : 196-201.

同被引文献17

  • 1何杰,郑声琴,乔颖娟,姚青,郭庆明,魏晓莹,黄培林.少突胶质细胞肿瘤染色体1p、19q和10q杂合性缺失与临床预后的关系[J].临床与实验病理学杂志,2006,22(4):444-448. 被引量:10
  • 2张淑坤,卢德宏,朴月善,蔡彦宁,徐庆中.即时荧光定量PCR微卫星分析技术检测少突胶质细胞肿瘤染色体1p/19q杂合性缺失[J].中华病理学杂志,2006,35(12):731-734. 被引量:9
  • 3Jeon YK,Park K,Park CK,et al.Chromosome 1p and 19q status and p53and p16 expression patterns as prognostic indicators of oligodendroglial tumors:a clinicopathological study using fluorescence in situ hybridization.Neuropathology,2007,27:10-20.
  • 4Kim SH,Kim H,Kim TS.Clinical,histological,and immunohistochemical features predicting 1p/19q loss of heterozygosity in oligodendroglial tumors.Acta Neuropathol,2005,110:27-38.
  • 5Brandes AA,Tosoni A,Cavallo G,et al.Correlations between O6-methylguanine DNA methyltransferase promoter methylation status,1p and 19q deletions,and response to temozolomide in anaplastic and recurrent oligodendroglioma:a prospective GICNO study.J Clin Oncol,2006,24:4746-4753.
  • 6M(o)llemann M,Wolter M,Felsberg J,et al.Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors.Int J Cancer,2005,113:379-385.
  • 7Hermisson M,Klumpp A,Wick W,et al.O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells.J Neurochem,2006,96:766-776.
  • 8Dumenco LL,Allay E,Norton K,et al.The prevention of thymic lymphomas in transgenic mice by human O6-alkylguanineDNA alkyltransferase.Science,1993,259:219-222.
  • 9Baer JC,Freeman AA,Newlands ES,et al.Depletion of O6alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells.Br J Cancer,1993,67:1299-1302.
  • 10Qian XC,Brent TP.Methylation hot spots in the 5' flanking region denote silencingofthe O6-methylguanine-DNA methyltransferase gene.Cancer Res,1997,57:3672-3677.

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部